Among the many novel concepts in managing immunotherapy is the potential for “pseudo-progression”. This unusual phenomenon is when a patient’s scans...
With positive trials of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab), in second line NSCLC and compared with...
Yesterday, news that the Checkmate 026 trial that compared the PD1 checkpoint inhibitor Opdivo (nivolumab) to standard chemotherapy as first line...
The transition of PD1 and PD-L1 inhibitors into the first line setting for at least some patients with advanced non-small cell lung cancer (NSCLC) is...
The medical community has made significant progress in understanding that lung cancer is not a single cancer, and are treating it accordingly. We’ve...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.